Safety and Anti-Tumour Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Titre officiel

A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumour Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer

Sommaire:

The study will consist of 2 parts: Part I (Dose Escalation) and Part II (Dose Expansion). In Part I, patients will participate in single, multiple, and long-term dosing periods using EPI-506 to determine safety, pharmacokinetics, the maximum tolerated dose, and preliminary indications of anti-tumour activity. Part I is an open-label, adaptive 3 + 3 design, dose-escalation study. Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. Enrolled patients may be allowed to escalate to a subsequent dose cohort after their initial twelve weeks. Additional patients may be enrolled at any safe dose level prior to or concurrent with enrolling patients in Part II. In Part II, 3 patient populations; post-abiraterone metastatic castration-resistant prostate cancer (mCRPC) but enzalutamide-naïve, post-enzalutamide mCRPC but abiraterone-naïve, and post-abiraterone and enzalutamide mCRPC will be studied at the recommended Phase 2 dose (RP2D) determined in Part I over 12 weeks of daily dosing. Approximately 120 patients (40 in each cohort) will be enrolled.

Description de l'essai

Primary Outcome:

  • Part I: Safety and tolerability assessed by vital signs, laboratory measurements, and frequency and severity of treatment-related adverse events
  • Part II: Prostate-specific antigen (PSA) response rate
Secondary Outcome:
  • Part I: Define the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)
  • Part I: Pharmacokinetics (PK) profile of EPI-506
  • Part I: Pharmacokinetics (PK) profile of EPI-002
  • Part I: Food effect on PK
  • Part I: PSA
  • Part II: Safety and tolerability assessed by vital signs, laboratory measurements, and frequency and severity of treatment-related adverse events
  • Part II: To evaluate the PK of EPI-506
  • Part II: To evaluate the PK of EPI-002
  • Part II: Time to PSA progression
  • Part II: Radiographic progression
  • Part II: Objective response

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer